Novel RET Inhibitor BOS172738 in RET-Altered Cancers Including RET Fusion–Positive NSCLC and RET Mutation–Positive Medullary Thyroid Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
BOS127238, a novel, highly selective RET inhibitor, was associated with a manageable safety profile and preliminary efficacy in a phase I study in RET-altered solid tumors.
Format: Microsoft PowerPoint (.ppt)
File Size: 444 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)

Released: December 1, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Released: December 1, 2021

PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue